Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, shares the findings from a subgroup analysis of the Phase I/II BRUIN study (NCT03740529), investigating pirtobrutinib in patients with mantle cell lymphoma (MCL) previously treated with a covalent BTK inhibitor. In this updated two-year analysis, patients with high-risk MCL, such as blastoid or pleomorphic variants, achieved responses consistent with the rest of the cohort, while responses differed in two other subgroups. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
International Conference of Malignant Lymphoma 2023 - Video Journals
BRUIN study: updated two-year subgroup analysis of pirtobrutinib for BTKi pre-treated MCL
Promising agents emerging for Richter’s transformation
Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, discusses promising therapeutic strategies for Richter’s transformation (RT), which is usually treated with R-CHOP chemotherapy and is associated with suboptimal response rates. Dr Cheah highlights the promise of novel agents being explored in this field, such as pirtobrutinib and epcoritamab. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
The role of epcoritamab in third-line or later LBCL
Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, comments on the emerging role of bispecific antibodies in the treatment of third-line or later large B-cell lymphoma (LBCL), particularly focusing on epcoritamab. Dr Cheah highlights the promising safety and efficacy data for epcoritamab, even in patients who have been exposed to CAR-T therapy, and further comments on the manageable side effect profile of this agent. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.